(Q37627874)

21 August 2017

1 reference

title

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations (English)

1 reference

21 August 2017

1 reference

1 reference

Kyle J Ellis

1

1 reference

21 August 2017

George A Stouffer

series ordinal

2

1 reference

21 August 2017

Howard L McLeod

series ordinal

3

1 reference

21 August 2017

Craig R Lee

series ordinal

4

1 reference

21 August 2017

publication date

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1799-1817

1 reference

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Current antiplatelet therapies: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Antiplatelet drug nonresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Platelet function testing in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Methods for the measurement of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Current options in platelet function testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Pharmacokinetic drug interaction profiles of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The genetic polymorphism of drug transporters: functional analysis approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

New aspects in the pathogenesis of diabetic atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Platelet inhibition by insulin is absent in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Can we override clopidogrel resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

Clopidogrel: a review of its use in the prevention of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.143

21 January 2018

Identifiers

DOI

10.2217/PGS.09.143

1 reference

21 August 2017

1 reference